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Ddue to the in-depth detail we now have because of the com-
puterization of our intensive insulin therapy. We are able to
look beyond just the average BG values to have a better un-
derstanding of what may be themain factor affecting patient
outcomes related to BG management.Study Limitations
A possible limitation is that this was not a blinded study,
which could introduce bias into the study. However, be-
cause a computer software program was used to determine
the rate of the insulin infusion and any glucose administra-
tion, the caregiver was unable to indirectly influence a pa-
tient’s BG levels.
Another possible limitation is that we did not draw
markers of inflammation. Some studies have found that
tight glycemic control affects these inflammatory markers
and thus may affect long-term patency of the bypass grafts
and reduce ischemic events.22-24CONCLUSIONS
The findings of this study suggest that tight glucose con-
trol (90–120 mg/dL) in patients undergoing CABGmay not
be warranted in the short term. Therefore, we suggest that
all patients who undergo CABG should have a more liberal
BG target level of 120 to 180 mg/dL while hospitalized,
which is line with the current STS guidelines. Further
work is needed to determine the optimal BG level for
long-term benefit and the optimal level for patients under-
going surgery for valvular heart disease.References
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Dr Harold Lazar (Boston, Mass). I enjoyed your presentation
and appreciate you sending me the manuscript well ahead of time.
My only conflict is that I have received grant support from the Eli
Lilly Company to study the effects of glycemic control during car-
diac surgery.
Last month at the American Surgical Association, my col-
leagues and I presented a article in which we prospectively ran-
domized 82 diabetic patients undergoing CABG to receive an
aggressive glycemic group, 90 to 120, or a moderate group, 120
to 180. We found no difference in 30-day mortality, myocardial in-
farctions, neurologic complications, deep sternal wound infec-
tions, or incidence of atrial fibrillation between groups, which
was similar to your results. The patients with more aggressive con-
trol had a higher incidence of hypoglycemic events, but this did not
result in any neurologic complications. We also concluded that ag-
gressive glycemic control increases the incidence of hypoglycemic
events but does not result in any significant improvement in clini-
cal outcomes that can be achieved with more moderate control.ery c February 2012
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DAlthough I am not surprised that moderate control is safe and
effective, the question is, why does more aggressive glycemic con-
trol offer no further advantages and is potentially harmful? Your
study and our own data may provide some potential mechanisms
for answering these questions.
First, many patients undergoing CABG are already receiving
cardioprotective agents. For example, in our own study, 100%
of patients were already receiving aspirin, a statin, and a beta-
blocker, and more than 50% of patients received an angioten-
sin-converting enzyme inhibitor. Thus, the added benefits of
aggressive glucose lowering may not have as great an effect in
reducing cardiovascular events as anticipated. So my first ques-
tion is, what was the incidence of use of these agents between
the groups in your own study?
Second, in our study, moderate glycemic control achieved an
average serum glucose of 135 versus 103 for the aggressive group.
Thus, evenwhen aiming for more moderate control, tight glycemic
control was still achieved. We found that using our paper algo-
rithm, both the moderate and aggressive groups remained in their
respective target ranges 100% of the time. Do you think that the
computerized Glucommander system could have accounted for
the wider variation in your patients receiving the more aggressive
control? Less than 50% of patients in your study were diabetic.
Could the larger incidence of nondiabetic patients have made
tighter glycemic control more vulnerable to these hypoglycemic
episodes?
Third, we have shown in our series that one of the benefits of
glycemic control is that markers of inflammation, such as free fatty
acids, are significantly reduced. In our recent study, aggressive
control actually resulted in a significant decrease in free fatty acids
compared with the more moderate control. This ultimately may re-
sult in long-term benefits, such as improved graft patency and re-
duced ischemic events. Did you measure any inflammatory
markers and do you have any long-term follow-up for these pa-
tients as to the incidence of recurrent ischemic episodes and the
need for re-revascularization? It may turn out that more aggressive
control might still have some hidden long-term benefits.The Journal of Thoracic and CaFinally, as we have seen in our earlier studies, moderate glyce-
mic control alone has resulted in a significant decrease in morbid-
ity and mortality, which may be difficult to improve on with more
aggressive control.
In summary, although I agree that the optimal range for gly-
cemic control in cardiac surgery patients is 120 to 180, we
should all remember that although the exact value for achieving
optimal perioperative glycemic control is still unknown and the
subject of numerous studies and intense debate, the concept of
perioperative glycemic control using continuous insulin infu-
sions in our patients is well established and its importance is
not debatable.
Dr Desai. In terms of whether we had data regarding cardiac
medications that the patients were taking, we did collect medica-
tion data for all the patients who were enrolled in the study, but
this was not analyzed. In regard to inflammatory markers, we
did measure erythrocyte sedimentation rate and C-reactive protein
levels in all patients who were enrolled in this study. I do not have
the data here on the levels in the strict group versus the liberal
group.
In terms of the computer algorithm versus the paper algorithm
and the wide variation, I think having our study open to a lot of
nondiabetic patients did contribute to the wide variability. These
are patients who are not normally hyperglycemic, but because
of the stress of surgery and the other factors involved, their glu-
cose levels were severely elevated to the point that they are started
on insulin infusions. We also noticed that once we got to approx-
imately 48 hours after the surgery, the patients were starting to
take an oral diet. Because of this, we also noticed large spikes
in their glucose, which the computer algorithm does not currently
into account. Deviations from target range was common because
of this phenomenon and have been seen in other similar studies.
It is excellent, Dr Lazar, that your study was able to maintain pa-
tients 100% in their target range. We believe further work needs to
be done with the Glucommander computerized system in regard to
adjusting the algorithm once the patients start taking an oral diet
after their surgery to maintain their target range.rdiovascular Surgery c Volume 143, Number 2 325
